tag@treatmentactiongroup.org

HCV

cover of the publication: Illustrated Glossary for Long-Acting Technologies, July 2021

Illustrated Glossary for Long-Acting Technologies

The Illustrated Glossary for Long-Acting Technologies compiles frequent terms and concepts used in the research and development of long-acting technologies. The glossary is a non-exhaustive list and the graphics are artistic renderings meant to spur discussion and assist with community treatment literacy. 
Read more

Launch of Public Health Partnership to Tackle the Silent Epidemic of Hepatitis C in Low- and Middle-Income Countries

The Drugs for Neglected Diseases initiative (DNDi), Médecins Sans Frontières (MSF), FIND, the global alliance for diagnostics, and the Treatment Action Group are joining forces to tackle a ‘silent’ public health injustice: the continuing disparities in access to diagnostics and treatment for the hepatitis C virus (HCV) in low- and middle-income countries (LMICs), home to 75% of those living with this viral illness.
Read more
Pipeline Report 2021 cover

2021 Pipeline Report

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Read more

Research in Action Awards 2021

On November 16, we honored CDC Director Rochelle Walensky, MD, MPH; Ivy Kwan Arce, activist, mother, and artist living with HIV; and Erica Lessem, MPH, former TAG Deputy Executive Director.
Read more
cover of TAG's 2020 annual report. It reads: progress in the fight for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and Hepatitis C virus

2020 Annual Report

As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.
Read more

TAG Comments on NIST’s Proposed Rulemaking Changes

TAG submitted comments in response to the National Institute of Standards and Technology's (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically important to public health and the right to science.
Read more

Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics

TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for diagnostics as a global norm; and increasing investments in alternative rapid molecular tests to promote competition and improve access.
Read more
Back To Top